SK pharmteco has successfully completed a regulatory inspection of its small molecule North America facility in La Porte, Texas conducted by the U.S. Food and Drug Administration (FDA). After a thorough review of the facility’s quality systems and manufacturing operations, the FDA completed the inspection without issuing a Form 483. This “No Action Indicated” (NAI) status confirms that the site complies with the highest regulatory standards. The general inspection included tours of the war...